Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients

Parameters Patients (N = 99)
Age (years) 57.98 ± 10.33
Gender (Male/Female) 89/10
Hepatitis history
 No hepatitis history (n/%) 3 (3.1)
 HBV (n/%) 94 (94.9)
 HCV (n/%) 2 (2.1)
Drink (n/%) 43 (43.4)
Cirrhosis (n/%) 55 (55.6)
Tumor distributiona (%) 20.0 (5.0–30.0)
Number of nodules
 1 (n/%) 30 (30.1)
  > 1 (n/%) 69 (69.9)
  < =3 (n/%) 54 (54.5)
  > 3 (n/%) 45 (45.5)
Largest nodule size (cm) 4.3 (2.1–8.3)
Portal vein invasion (n/%) 29 (29.3)
 Main portal vein invasion (n/%) 8 (8.1)
 First branch invasion (n/%) 8 (8.1)
 Second branch invasion (n/%) 13 (13.1)
Hepatic vein invasion (n/%) 17 (17.2)
ECOG performance status
 0 (n/%) 70 (70.7)
 1 (n/%) 29 (29.3)
Child-pugh Stage
 A (n/%) 91 (91.2)
 B (n/%) 8 (8.1)
BCLC Stage
 A (n/%) 24 (24.2)
 B (n/%) 35 (35.4)
 C (n/%) 40 (40.4)
Laboratory Indexes
 WBC abnormal (n/%) 31 (31.3)
 RBC abnormal (n/%) 16 (16.2)
 ANC abnormal (n/%) 26 (26.3)
 HB abnormal (n/%) 28 (28.3)
  80~ 100 g/L 5 (5.1)
   > 100 g/L 23 (23.2)
 PLT abnormal (n/%) 28 (28.3)
  50~ 70 × 109/L 19 (19.2)
   > 70 × 109/L 9 (9.1)
 ALB abnormal (n/%) 10 (10.1)
 TP abnormal (n/%) 20 (20.2)
 TBIL abnormal (n/%) 17 (17.2)
  21~ 34 μmol/L 13 (13.1)
  34~ 51 μmol/L 4 (4.0)
 TBA abnormal (n/%) 29 (29.3)
 ALT abnormal (n/%) 22 (22.2)
 AST abnormal (n/%) 31 (31.3)
  1~ 2ULN 25 (25.2)
  2~3ULN 6 (6.1)
 ALP abnormal (n/%) 19 (19.2)
 BCr abnormal (n/%) 10 (10.1)
 BUN abnormal (n/%) 9 (9.1)
 AFP abnormal (n/%) 55 (55.6)
  20.0~ 400 ng/ml 21 (21.2)
   > 400 ng/ml 34 (34.3)
 CEA abnormal (n/%) 12 (12.1)
 CA199 abnormal (n/%) 19 (19.2)
Previous treatment
 cTACE (n/%) 39 (39.4)
 cTACE times 1 (1~ 2)
 Surgery (n/%) 66 (66.7)
 Systematic chemotherapy (n/%) 5 (5.1)
 Radiofrequency ablation (n/%) 17 (17.2)
 Targeted therapy (n/%) 1 (1.0)
Chemoembolization reagents
 Adriamycin (n/%) 4 (4.1)
 Epirubicin (n/%) 95 (95.9)
  1. Data was presented as count (%), mean ± standard deviation or median (25th–75th)
  2. aTumor distribution: percentage of tumor in the whole liver. HBV Hepatic b virus, HCV Hepatic c virus, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, WBC While blood cell, RBC Red blood cell, ANC Absolute neutrophil count, HB Hemoglobin, PLT Platelet, ALB Albumin, TP Total protein, TBIL Total bilirubin, TBA Total bile acid, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALP Alkaline phosphatase, BCr Blood creatinine, BUN Blood urea nitrogen, AFP Alpha fetoprotein, CEA Carcino-embryonic antigen, CA199 Carbohydrate antigen199, cTACE Conventional transarterial chemo-embolization